Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Leuven – page 63

1 142 clinical trials in Leuven, Belgium across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Leuven at a glance
1 142
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 142 trials in Leuven

Open in trial search

K-ras gene mutation+3

Not recruiting

Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Batoprotafib
  • Sponsor:Novartis Pharma AG

Peripheral spondyloarthritis

Not recruiting

Study on Peripheral Spondyloarthritis: Comparing Methotrexate Disodium and Golimumab for Early Remission in Adult Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Universitair Ziekenhuis Gent

Dementia Alzheimer's type

Not recruiting

Study of BMS-986446 for Early Alzheimer's Disease Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Crohn's disease

Not recruiting

Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Myasthenia gravis

Not recruiting

Study on the Effects of Efgartigimod Alfa for Patients with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Breast cancer

Not recruiting

Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Chronic graft versus host disease

Not recruiting

Study on Axatilimab and Ruxolitinib for Patients with Newly Diagnosed Chronic Graft-Versus-Host Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Liver transplant rejection

Not recruiting

Study of QEL-001 (CAR T regulatory cell therapy) to prevent liver transplant rejection in patients with HLA-A2 positive donor organ

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Autologous T Regulatory Cells Expressing An Hla-A2-Specific Chimeric Antigen Receptor
  • Sponsor:Quell Therapeutics Limited

Short-bowel syndrome

Not recruiting

Study on the Long-Term Safety of Glepaglutide for Adults with Short Bowel Syndrome

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Leuven

What the registry says about research in the country

01 Gastrointestinal Research

Clinical investigations focusing on ulcerative colitis and innovative treatments for inflammatory bowel conditions. Studies include evaluation of novel therapies for short bowel syndrome and gastrointestinal motility disorders.

  • Inflammatory Bowel Disease Treatment
  • Gastrointestinal Motility Studies
  • Metabolic Disease Research

Current trials are examining drug absorption and therapeutic responses in patients with various digestive conditions.

02 Oncology Studies

Groundbreaking research in head and neck cancer treatments, including innovative radiotherapy approaches. Studies are also investigating new therapies for bladder cancer, focusing on early-stage interventions.

  • Advanced Cancer Therapies
  • Immunotherapy Research
  • Non-invasive Treatment Approaches

Emphasis on combining traditional treatments with novel therapeutic approaches to improve patient outcomes.

03 Neurological Disorders

Comprehensive studies on Alzheimer's disease and frontotemporal dementia, investigating disease progression and potential treatments. Research includes innovative approaches to understanding brain circuit functionality.

  • Cognitive Function Studies
  • Neurodegenerative Disease Research
  • Brain Imaging Technologies

Advanced imaging techniques are being utilized to track disease progression and treatment effectiveness.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.